Peptide Initiative

Peptide profile · Healing & Recovery

ARA-290 (Cibinetide)

A peptide that awakens your body's natural repair system to heal damaged nerves and reduce pain

Moderate human trialsNot FDA approved
Approximately 1-2 hours in circulation, but cellular effects last much longerHalf-life
Subcutaneous: ~100%Bioavailability (complete absorption); Intravenous: Immediate
1257.31Molecular weight, g/mol

Molecular formula

C51H84N16O21

CAS number
1208243-50-8
PubChem
91810664
Developed · 2008
Araim Pharmaceuticals Research Team, Araim Pharmaceuticals

Amino acid sequence

{Glp}-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser

Nerve RegenerationARA-290 actively regrows small nerve fibers that die from diabetes, neuropathy, or injury. Studies show real improvements in nerve density on corneal imaging.

9.5

Pain ManagementReduces neuropathic pain through both nerve repair and anti-inflammatory pathways. Users report decreased shooting pain and burning sensations.

8.5

Tissue ProtectionProtects pancreatic cells, organs, and tissues from stress damage. Works especially well in diabetes where tissues face constant oxidative harm.

9.0

Ratings out of 10.

1 – 8mg

Every documented dose level

PhaseDoseFrequencyRoute
28 days1 mgOnce dailySubcutaneous
28 days4 mgOnce dailySubcutaneous
28 days8 mgOnce dailySubcutaneous
4 weeks2 mgThree times weeklyIntravenous
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for treating small fiber neuropathy & managing neuropathic pain from diabetes or sarcoidosis

Best for

  • Treating small fiber neuropathy

    ARA-290 (Cibinetide) is particularly well-suited for individuals focused on treating small fiber neuropathy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Managing neuropathic pain from diabetes or sarcoidosis

    ARA-290 (Cibinetide) is particularly well-suited for individuals focused on managing neuropathic pain from diabetes or sarcoidosis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Supporting nerve regeneration after injury

    ARA-290 (Cibinetide) is particularly well-suited for individuals focused on supporting nerve regeneration after injury. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

  • Reducing chronic inflammation

    ARA-290 (Cibinetide) is particularly well-suited for individuals focused on reducing chronic inflammation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Consider alternatives if

Alternative approaches for healing & recovery supportConsult your healthcare provider for alternatives to ARA-290 (Cibinetide) based on your specific needs and medical history
Alternative healing peptidesBPC-157TB-500 (Thymosin Beta-4)GHK-Cu
Non-peptide recovery optionsPlatelet-Rich Plasma (PRP)Collagen supplementsPhysical therapy

Do not use if

  • Polycythemia vera or erythrocytosis
  • Uncontrolled hypertension
  • Pregnancy or breastfeeding
  • Known hypersensitivity to peptides
  • Concurrent use with certain cancer medications

Use with caution if

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about ARA-290 (Cibinetide) use
  • You have any chronic health conditions that require regular monitoring

Not sure?

Compare ARA-290 (Cibinetide) with similar peptides to find the best fit for your goals.

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

  • Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
  • Front of thighs—middle to upper portion of the outer leg
  • Back of upper arm—outer area (may need assistance from another person)

The ARA-290 (Cibinetide) injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.

3 common side effects · 3 serious

Emergency signs first, then what this page and MedlinePlus say.

ARA-290 is a synthetic innate repair receptor agonist that has completed Phase 2 clinical trials for small fiber neuropathy and is under active development.

Animal toxicology studies show a good safety margin with no organ damage or cytotoxicity at doses far exceeding therapeutic levels. Early clinical data from Phase 2 trials demonstrate tolerability with mild injection site reactions and transient headache as primary concerns.

However, immunogenicity remains a potential risk with repeated dosing of synthetic peptides, requiring anti-drug antibody monitoring. Long-term safety data beyond 12 weeks does not yet exist.

Evidence comes from preclinical toxicology studies, Phase 1 dose-escalation and safety data, and Phase 2 efficacy trials in small fiber neuropathy patients. The phase 2 trial enrolled 127 patients with a primary endpoint of safety and tolerability.

No serious adverse events directly attributable to ARA-290 were reported in early studies. Data suggests good safety at doses up to 1 mg subcutaneously twice weekly, but longer-term outcomes and immunogenicity assessments continue.


Common side effects · experienced by some users

Injection Site Reactions

Redness, mild swelling, or bruising at injection site lasting a few hours to a day

Management
Rotate injection sites, apply ice pack after injection, massage gently to improve absorption

Headache

Mild to moderate headache typically in first few hours after injection

Management
Stay hydrated, rest in a quiet space, over-the-counter pain reliever if needed

Dizziness

Brief dizziness or lightheadedness, especially when standing up quickly

Management
Rise slowly from sitting or lying, avoid sudden movements, inform your doctor if persistent

Serious side effects

Blood Clot Formation

Rare risk of thrombosis, especially in those with clotting disorders or immobility

Management
Report leg swelling, chest pain, or shortness of breath immediately. Regular movement and hydration help prevent.

Less commonElevated Blood PressureFatigue

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with ARA-290 (Cibinetide)
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

ARA-290 (Cibinetide) should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.


With other peptides

  • SafeAlpha Lipoic Acid — Enhances antioxidant protection and reduces inflammation to complement nerve regeneration
  • SafeBenfotiamine — Fat-soluble form of B1 vitamin that supports nerve function alongside ARA-290's regenerative effects
  • SafeVitamin B12 — Essential for nerve health and myelin formation, works synergistically with nerve repair

With medications

  • CautionErythropoietin (EPO) — Both activate similar pathways; combining could cause excessive red blood cell production
  • CautionUncontrolled antihypertensive medications — May cause dangerous blood pressure fluctuations
  • CautionAnticoagulants at high doses — May increase thrombosis risk

With supplements

  • SafeMultivitamins — Generally safe to take alongside ARA-290 (Cibinetide). Space doses apart if taking oral formulations to ensure optimal absorption.
  • SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Moderate human trials · first signs week 1-2: initial response (first two weeks)

Evidence level

Moderate human trials

(Phase 1-2)

80/100

Regulatory status

Not FDA approved

Onset of effects

Moderate

(1-2 weeks)


How it works

ARA-290 mimics a naturally occurring peptide (erythropoietin fragment) that reduces inflammation and protects nerves from damage.

It's being developed for conditions like diabetes-related nerve pain where inflammation damages nerve tissues.

The deeper mechanism

ARA-290 (cibinetide) is an erythropoietin-derived peptide that activates the heterodimeric receptor (CD131/βcR) without activating erythropoietin-induced erythropoiesis.

It promotes anti-inflammatory and tissue-protective signaling through JAK/STAT pathways, reducing inflammatory cytokine production and improving neuronal survival in diabetic neuropathy.


What to expect

  1. Week 1-2: Initial Response (First two weeks)

    What you might notice

    • You may notice improved energy, better sleep, or mild improvement in pain
    • Injection site reactions are most common now
    • Your body's repair systems are just starting to activate

    What's normal

    • Initial response to ARA-290 (Cibinetide) is beginning at the cellular level
    • Different individuals experience ARA-290 (Cibinetide)'s onset at different rates
    • Transient systemic effects from initial ARA-290 (Cibinetide) exposure are common

    What's next

    • Maintain consistent ARA-290 (Cibinetide) administration as prescribed
    • Document subjective effects and physical markers daily
    • Schedule a check-in with your provider about initial observations
  2. Week 3-8: Noticeable Changes (Weeks 3-8)

    What you might notice

    • Pain reduction becomes more apparent
    • Inflammation starts decreasing
    • Some users report better blood sugar control
    • Nerve regeneration is happening but may not be felt yet

    What's normal

    • ARA-290 (Cibinetide) is now achieving steady-state pharmacokinetics
    • Measurable changes aligned with ARA-290 (Cibinetide)'s mechanism may appear
    • Initial adjustment effects typically resolve by this point

    What's next

    • Maintain ARA-290 (Cibinetide) dosing exactly as established
    • Track progress toward intended outcomes in detail
    • Review lab work or biomarker changes with your healthcare team
  3. Week 9-16: Significant Improvement (Weeks 9-16)

    What you might notice

    • Neuropathic pain noticeably reduced
    • Increased sensation in feet (if neuropathy was present)
    • Better energy and mood
    • Healing effects becoming measurable

    What's normal

    • ARA-290 (Cibinetide) has achieved stable, long-term homeostatic integration
    • Sustained efficacy of ARA-290 (Cibinetide) remains consistent
    • Chronic ARA-290 (Cibinetide) effects remain stable and predictable

    What's next

    • Maintain your established ARA-290 (Cibinetide) protocol for sustained benefits
    • Continue periodic monitoring to confirm ARA-290 (Cibinetide) efficacy
    • Review comprehensive ARA-290 (Cibinetide) response with your provider
  4. Month 4+: Full Benefits Realized (4+ months)

    What you might notice

    • Maximum nerve fiber regrowth visible on corneal imaging
    • Sustained pain reduction
    • Improved daily function and quality of life
    • Benefits continue with ongoing treatment

    What's normal

    • Full therapeutic effects of ARA-290 (Cibinetide) are well-characterized at this point
    • Maintenance of ARA-290 (Cibinetide)'s therapeutic effects is typical
    • Tolerance patterns with ARA-290 (Cibinetide) are generally stable over months

    What's next

    • Comprehensive assessment of ARA-290 (Cibinetide) efficacy should be conducted
    • Discuss long-term continuation, cycling, or protocol modifications
    • Continue regular monitoring of relevant biomarkers or symptoms

Signs it's working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to ARA-290 (Cibinetide) over time
  • Reduction in symptom frequency or severity

Signs it's working

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing results?

Common reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

3 registered studies, none currently enrolling.

3registered studies
0recruiting now
0phase 3 or 4
0with published results

By phase

Phase 2

3

A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.

What kind of research

Gave the drug

3

Records only

0

About 97 people took part in the studies that actually administered ARA-290 (Cibinetide). Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.


Most recent

  • NCT06626971 Phase 2Terminated9 enrolled

    The Use of ARA290 for the Treatment of Diabetic Macular Oedema

    Belfast Health and Social Care Trust

  • NCT02039687 Phase 2Completed64 enrolled

    Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis

    Araim Pharmaceuticals, Inc.

  • NCT01933529 Phase 2Unknown24 enrolled

    ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)

    Claes-Göran Östenson

See all 3 trials for ARA-290 (Cibinetide)

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when ARA-290 (Cibinetide) is named as an intervention; studies that only mention it in passing are not.

How is ARA-290 different from regular erythropoietin (EPO)?

ARA-290 is an 11-amino acid fragment derived from EPO. While EPO stimulates red blood cell production, ARA-290 keeps only the tissue-protective, anti-inflammatory, and nerve-regenerating effects. It activates different cellular pathways without causing the problematic increase in red blood cells that EPO does.

How long before I see results from ARA-290?

Most people notice initial improvements like better sleep or reduced inflammation within 1-2 weeks. Significant pain reduction typically appears by week 6-8. However, nerve fiber regeneration (visible on corneal scans) takes 8-16 weeks to become really apparent. Patience is key with this one!

Can ARA-290 cure neuropathy permanently?

ARA-290 regenerates nerve fibers and reduces pain, which is remarkable. However, it's best thought of as a treatment that needs to be continued, especially if the underlying cause (like diabetes) isn't completely controlled. Some improvements may be permanent, but ongoing treatment typically provides best results.

Is ARA-290 safe for diabetics?

Yes, and it's actually particularly helpful for diabetics with neuropathy. Clinical trials showed it improves glucose control and reduces neuropathic pain in type 2 diabetics. However, blood pressure and red blood cell counts should be monitored, as with any peptide therapy.

Can I use ARA-290 if I have cancer history?

This is one of the contraindications. Because ARA-290 activates cell growth and repair pathways, it's considered unsafe for people with active cancer or recent cancer history. Always discuss your complete medical history with your doctor before starting.

How do I inject ARA-290?

Subcutaneous injection (under the skin) is preferred. Common sites include the abdomen, thigh, or upper arm. Some clinical trials used intravenous administration, but subcutaneous is easier for self-administration. Your doctor will provide detailed injection training.

What happens if I stop taking ARA-290?

Many benefits persist because nerve fibers that regenerate tend to stay regenerated. However, inflammation may gradually return and pain might increase over time. This is why continued treatment or maintenance dosing is usually recommended for best long-term results.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for ARA-290 (Cibinetide), on one page.

ARA-290 (Cibinetide) dosing protocol

Medical disclaimer

ARA-290 (Cibinetide) is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 11, 2026